grant
Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses
Organization NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESLocation UNITED STATES
NIHUS FederalResearch GrantFY20250-11 years old12-20 years old2 year old2 years of age21+ years old5 year old5 years of age7S Gamma GlobulinAIDS VirusAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusActive ImmunizationActive immunityActive vaccinationAcuteAcylneuraminyl hydrolaseAdolescenceAdultAdult HumanAge MonthsAirway mucosaAmino AcidsAnti-viral AgentsAntibodiesAntibody ResponseAntigensApoptosisApoptosis PathwayAsthmaAttenuatedAttenuated VaccinesBlindedBlood SerumBovine SpeciesBronchial AsthmaCRADACattleCessation of lifeChildChild YouthChildhoodChildren (0-21)Chimera ProteinChimeric ProteinsClinicalClinical ResearchClinical StudyClinical Treatment MoabClinical TrialsClinical Trials NetworkCodonCodon NucleotidesCollaborationsComplementary DNAComplicationConduct Clinical TrialsCooperative Research and Development AgreementDNA mutationData AnalysesData AnalysisDeathDeletion MutationDevelopmentDoseEarly-Stage Clinical TrialsElementsEnrollmentEvaluationExperimental ModelsFusion ProteinGene TranscriptionGenesGeneticGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGenomeGoalsHIVHPIV1HPIV3Half-LifeHeadHealthHemadsorption Type 2 VirusHemadsorption Virus 1Hemadsorption Virus 2HemagglutininHospital AdmissionHospitalizationHumanHuman Immunodeficiency VirusesHuman MetapneumovirusHuman Parainfluenza Virus 1Human Parainfluenza Virus 3IFNIMPAACTIgGImmune responseImmunityImmunizationImmunoglobulin GInfantInfectionInterferonsInternational Maternal Pediatric Adolescent AIDS Clinical TrialsInternational Maternal Pediatric Adolescent HIV/AIDS Clinical TrialsKansasLAV-HTLV-IIILaboratoriesLaboratory StudyLive-attenuated VaccineLower Respiratory Tract InfectionLower respiratory infectionLymphadenopathy-Associated VirusManuscriptsMarylandMedicalMissense MutationModelingModern ManMonoclonal AntibodiesMutationN-Acylneuraminate GlycohydrolasesNeuraminidaseORFsOligosaccharide SialidaseOpen Reading FramesOrthopneumovirusPara-Influenza Virus Type 1Para-Influenza Virus Type 3ParticipantPassive ImmunityPhasePhase 1 Clinical TrialsPhase I Clinical TrialsPhase I StudyPhenotypePlacebo ControlPlacebosPneumoviridaePneumovirinaePneumovirusPolymerasePopulationPositionPositioning AttributePreparationProgrammed Cell DeathProtein Coding RegionProteinsPublicationsRNA ExpressionRNA chemical synthesisRNA replicationRNA synthesisRSV VaccinesRSV infectionRandomizedReportingResearchRespiratory DiseaseRespiratory MucosaRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesRespiratory System DiseaseRespiratory System DisorderRespiratory syncytial virusSafetySamplingScientific PublicationSeasonsSerotypingSerumSham TreatmentSialidaseSubunit VaccinesSystemToddlerTranscriptionUniversitiesUpregulationVaccinationVaccine Clinical TrialVaccine DesignVaccinesViralViral AntigensViral DiseasesViral GenesViral PathogenesisVirusVirus DiseasesVirus-HIVadolescence (12-20)adulthoodage 2 yearsage 5 yearsage groupaged 2 yearsaged two yearsaminoacidanti-viral compoundanti-viral drugsanti-viral medicationanti-viral therapeuticanti-viralsassess effectivenessattenuateattenuatesattenuationbovidbovinecDNAcowdata interpretationdesigndesigningdetermine effectivenessdevelopmentalearly childhoodeffectiveness assessmenteffectiveness evaluationenrollevaluate effectivenessevaluate vaccinesexamine effectivenessexo alpha sialidasefive year oldfive years of agegenome mutationhost responseimmune system responseimmunogenimmunogenicimmunogenicityimmunoresponseimprovedinfancyinfantilekidslead candidatelive vaccinelive vaccinesmAbsmaternal immunizationmaternal vaccinationmissense single nucleotide polymorphismmissense single nucleotide variantmissense variantmonoclonal Absmortalitymucosal siteparainfluenza virusparainfluenza virus type 1parainfluenza virus type 3particlepassive immunoprophylaxispathogenpediatricphase 1 studyphase I protocolplacebo controlledplasmid vaccinepre-clinical developmentpre-clinical studypreclinical developmentpreclinical studypreparationsrandomisationrandomizationrandomized placebo controlled studyrandomly assignedrecombinant virusrespiratoryresponsereverse geneticsseropositivesham therapytherapeutic candidatetwo year oldtwo years of agevaccine candidatevaccine evaluationvaccine screeningvaccine strategyvaccine testingvectorvector vaccineviral RNAviral infectionvirologyvirus RNAvirus antigenvirus infectionvirus pathogenesisvirus-induced diseasevolunteeryoungster
Description preview
We are following two strategies to develop a live-attenuated pediatric RSV vaccine. (i) Our primary strategy is to develop live-attenuated RSV strains, with attenuation provided mainly by deletion of one of several nonessential genes and by missense and codon-deletion mutations that are mainly in the L polymerase and have been stabilized against…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click